Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers.

Expression of ras p21 was examined with monoclonal antibody RASK-3 in normal, benign hyperplasic, and cancerous prostates. In patients with stage D2 disease who received endocrine therapy, the relation between ras p21 expression, response to therapy, and prognosis was studied. In these patients, R 1881-binding protein (androgen receptor and progestin-binding protein) was also examined. Non-cancerous cells and most cancer cells from stage A patients did not express ras p21, while expression increased with both higher staging and grading. Staging pelvic lymphadenectomy was done in some stage A2-C cases, and presence of nodal metastasis was correlated with ras p21 expressions in the primary tumours. In stage D2, there was no correlation between ras p21 expression and R 1881-binding protein. Response to therapy and survival did not correlate with expression of ras p21, but was influenced by presence of R 1881-binding protein.

[1]  P. Hand,et al.  Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[3]  G. Fleuren,et al.  Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome. , 1988, Archives of pathology & laboratory medicine.

[4]  M. Noguchi,et al.  Immunohistochemical demonstration of ras p21 oncogene product in normal, benign, and malignant human thyroid tissues , 1988, Cancer.

[5]  B. Gusterson,et al.  Immunohistochemical localization of c-erbB-2 in human breast carcinomas. , 1987, Molecular and cellular probes.

[6]  G. Lanza.  ras p21 oncoprotein expression in human colonic neoplasia—an immunohistochemical study with monoclonal antibody RAP‐5 , 1988, Histopathology.

[7]  R. Kurzrock,et al.  Expression of p21ras in fresh primary and metastatic human colorectal tumors. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Hand,et al.  Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. , 1986, Cancer research.

[9]  S. Hirohashi,et al.  Histologic demonstration of antigens reactive with anti-p21 ras monoclonal antibody (RAP-5) in human stomach cancers. , 1986, Journal of the National Cancer Institute.

[10]  S. Brosman,et al.  Ras related oncogene protein as a tumor marker in transitional cell carcinoma of the bladder. , 1987, The Journal of urology.

[11]  M. Viola,et al.  Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Merlo,et al.  Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization. , 1987, Cancer research.

[13]  K. Fan,et al.  Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of P21 protein as a predictor for bone metastasis. , 1988, The Journal of urology.

[14]  H. Fuse,et al.  Androphilic protein studied histochemically in stage D2 prostatic cancer , 1988, Cancer.

[15]  P. Scardino,et al.  The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate , 1983, Journal of surgical oncology.

[16]  J. Isaacs,et al.  Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. , 1988, The Journal of urology.

[17]  J. A. van der Korput,et al.  Expression of cellular oncogenes in human prostatic carcinoma cell lines. , 1985, Biochemical and biophysical research communications.

[18]  H. Abou-Issa,et al.  Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents. , 1985, Biochemical and biophysical research communications.

[19]  P. Smith,et al.  Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. , 1987, Urologia internationalis.

[20]  Austin Ge,et al.  Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue. , 1989 .

[21]  Y. Kawakami,et al.  The relationship of clinical classification to ras p21 expression in human non-small cell lung cancer. , 1988, Oncology.

[22]  P. Walsh,et al.  Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. , 1989, The Journal of urology.

[23]  H. Ikeda,et al.  Preparation of anti-ras Mr 21,000 protein monoclonal antibodies and immunohistochemical analyses on expression of ras genes in human stomach and thyroid cancers. , 1988, Cancer research.

[24]  D. Tindall,et al.  A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. , 1987, Progress in clinical and biological research.

[25]  M. Handcock,et al.  Ras oncogene p21 levels parallel malignant potential of different human colonic benign conditions. , 1987, Archives of surgery.

[26]  D. Slamon,et al.  Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. , 1988, Cancer research.

[27]  D. Spandidos,et al.  Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. , 1986, British Journal of Cancer.

[28]  T. Stamey,et al.  Activated ki‐ras oncogene in human prostatic adenocarcinoma , 1987, The Prostate.

[29]  T. Stamey,et al.  Oncogenes: a review with relevance to cancers of the urogenital tract. , 1986, The Journal of urology.

[30]  P. Hand,et al.  Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases , 1984, Nature.

[31]  A. Thor,et al.  Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues. , 1987, The American journal of pathology.

[32]  R. Matusik,et al.  Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. , 1986, Cancer research.

[33]  A. Ghosh,et al.  Immunohistochemical detection of ras oncogene p21 product in benign and malignant mammary tissue in man. , 1986, Journal of clinical pathology.

[34]  Scott Ww.  Carcinoma of the prostate. , 1956, The New England journal of medicine.

[35]  M. Viola,et al.  Expression of ras oncogene p21 in prostate cancer. , 1986, The New England journal of medicine.

[36]  A. Balmain,et al.  Immunocytochemical demonstration of p21 ras family oncogene product in normal mucosa and in premalignant and malignant tumours of the colorectum. , 1985, British journal of cancer.